1420775-77-4

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 683738-44-5 2-aminopyridine-4-thiol 

Downstream Products

• 1369414-22-1 4-amino-N-[3-(diethylamino)propyl]-3-(4-{[(3-fluorophenyl)carbamoyl]-amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide 
• 1420775-79-6 4-amino-3-(4-(3-(3-fluorophenyl)ureido)phenyl)thieno[3,2-c]pyridine-7-carboxylic acid 
• 1420775-78-5 methyl 4-amino-3-(4-(3-(3-fluorophenyl)ureido)phenyl)thieno[3,2-c]pyridine-7-carboxylate 
• 1227939-82-3 ABT-348 

Relevant academic research and scientific papers

Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

The invention relates to a packaging comprising a multitude (A) of at least 2 administration units comprising polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide; or (B) of at least 2 administration units comprising polymorphic solvated or desolvated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide.

PROCESSES TO MAKE PROTEIN KINASE INHIBITORS

Processes to prepare compounds that inhibit protein kinases such as Aurora kinases and the VEGFR and PDGFR families of kinases are discussed.

KINASE INHIBITOR WITH IMPROVED AQUEOUS SOLUBILITY

4-Amino-N- [3 -(diethylamino)propyl]-3 -(4- { [(3 - fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide which inhibits protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved aqueous solubility profile, compositions containing 4-amino-N-[3- (diethylamino)propyl]-3-(4- {[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2- c]pyridine-7-carboxamide and methods of treating diseases using 4-amino-N-[3- (diethylamino)propyl]-3-(4- {[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2- c]pyridine-7-carboxamide are disclosed.